ALVO
Alvotech
$3.34
-1.18%
$1.0B
No data for this timeframe.
Vol
Market Cap$1.0B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (75%)
Reddit Sentiment71° Bullish
SEC Reports4
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. N4·CIK 0001898416·Prev Close $3.38
Recent Activity
May 11, 2026
Press
Alvotech announced that the FDA completed a routine cGMP surveillance inspection of its Reykjavik facility, issuing a Fo
Impact 4/10
May 11, 2026
SEC
Alvotech announced FDA completed a cGMP surveillance inspection of its manufacturing facility, issuing a Form 483 with o
PRESS-RELEASE — Impact 6/10
May 11, 2026
announcement
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
<p><b>REYKJAVIK, ICELAND – May 11, 2026</b> – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnol
May 6, 2026
SEC
Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowdown. Despite the dec
PRESS-RELEASE — Impact 6/10
May 6, 2026
SEC
Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the $0.06 consensus, due
PRESS-RELEASE — Impact 7/10
Apr 24, 2026
Press
Alvotech announced it will release its Q1 2026 financial results on May 6, 2026, followed by a webcast and live Q&A on M
Impact 2/10
Price Targets
$13.83
+314.2% upside
Strong Buy
Current $3.34
Low $4.00
Median $7.50
High $50.00
6 analysts
$4.00
$50.00
Analyst Ratings
3Strong Buy
6Buy
2Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 24, 2026 | UBS | MAINTAIN | Buy → Buy |
| Mar 24, 2026 | Barclays | MAINTAIN | Underweight → Underweight |
| Dec 9, 2025 | Barclays | INITIATE | Underweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.00 ▲ +98.8% | $-0.00 — $-0.00 | -103% YoY | 1 |
| Next Q | $0.01 ▲ +112.2% | $0.01 — $0.01 | 109% YoY | 1 |
| Current FY | $0.06 ▲ +797.5% | $0.02 — $0.10 | 157% YoY | 2 |
| Next FY | $0.18 ▼ -2.2% | $-0.01 — $0.45 | 217% YoY | 4 |
Latest Reports
NEUTRAL
Press
4/10
Alvotech announced that the FDA completed a routine cGMP surveillance inspection of its Reykjavik facility, issuing a Fo
May 11, 2026
BULLISH
PRESS-RELEASE
6/10
Alvotech announced FDA completed a cGMP surveillance inspection of its manufacturing facility, issuing a Form 483 with o
May 11, 2026
BEARISH
PRESS-RELEASE
6/10
Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowdown. Despite the dec
May 6, 2026
Reddit Sentiment
71°
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
BULLISH
PRESS-RELEASE
6/10
Alvotech announced FDA completed a cGMP surveillance inspection of its manufacturing facility, issui
May 11, 2026
BEARISH
PRESS-RELEASE
6/10
Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowd
May 6, 2026
BEARISH
PRESS-RELEASE
7/10
Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the
May 6, 2026
NEUTRAL
PRESS-RELEASE
3/10
Alvotech announced it will release Q1 2026 financial results on May 6, 2026, with a webcast and Q&A
Apr 24, 2026
NEUTRAL
4/10
Alvotech announced that the FDA completed a routine cGMP surveillance inspection of its Reykjavik fa
May 11, 2026
NEUTRAL
2/10
Alvotech announced it will release its Q1 2026 financial results on May 6, 2026, followed by a webca
Apr 24, 2026
NEUTRAL
3/10
Alvotech announced it will release its Q4 and full-year 2025 financial and operating results on Marc
Mar 4, 2026
Current analyst consensus: Buy (75% buy). Based on 12 analysts: 3 strong buy, 6 buy, 2 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$13.83 mean target
+314.2% upside
Strong Buy (2.00)
$4.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $3.34 |
| Target Low | $4.00 |
| Target Mean | $13.83 |
| Target Median | $7.50 |
| Target High | $50.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.00 | $-0.00 | $-0.00 | -103.3% | +98.8% | — | $0.1B | -18.6% | 1 |
| Next Q 2026-09-30 |
$0.01 | $0.01 | $0.01 | 108.9% | +112.2% | — | $0.2B | 52.0% | 1 |
| Current FY 2026-12-31 |
$0.06 | $0.02 | $0.10 | 156.5% | +797.5% | 0↑ 2↓ | $0.7B | 12.2% | 2 |
| Next FY 2027-12-31 |
$0.18 | $-0.01 | $0.45 | 216.5% | -2.2% | 1↑ 1↓ | $0.8B | 18.6% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.001 | |
| 7d ago | $-0.060 | +0.059 |
| 30d ago | $-0.080 | +0.079 |
| 60d ago | $0.069 | -0.070 |
| 90d ago | $0.069 | -0.070 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 24, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Dec 9, 2025 | Barclays | INITIATE | — | Underweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| Apr 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| Mar 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| Feb 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| Jan 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
71°
Bullish
Bearish
Neutral
Bullish
3 mentions
3 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 11, 2026
announcement
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
<p><b>REYKJAVIK, ICELAND – May 11, 2026</b> – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and ma
May 11, 2026
earnings
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
<p align="center"><strong><em>- Company remains on track for BLA resubmissions in the second quarter</em></strong><br></p>
May 6, 2026
earnings
Alvotech Q1 2026 Financial Results
<p><b>Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)</b><br></p>
May 6, 2026
earnings
Alvotech Q1 2026 Financial Results
<p>REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- <br></p> <p><strong>Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)</strong><
May 6, 2026
earnings_calendar
ALVO Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
other
Alvotech Announces a Change in its Executive Team
<p align="left">REYKJAVIK, Iceland, April 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing
Apr 30, 2026
other
Alvotech Announces a Change in its Executive Team
<p><b>REYKJAVIK, </b><b>ICELAND (April 30, 2026) </b>— Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the developmen
Apr 24, 2026
announcement
Alvotech to Report Financial Results for the First Quarter of 2026
<p><b>REYKJAVIK, </b><b>ICELAND (April 24, 2026) </b>— Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing
Apr 24, 2026
earnings
Alvotech to Report Financial Results for the First Quarter of 2026
<p align="left">REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology com
Mar 30, 2026
earnings
Alvotech files Annual Report with the SEC
<p><b>REYKJAVIK, </b><b>ICELAND (March 30, 2026) </b>— Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the f
Mar 30, 2026
regulatory
Alvotech Files Annual Report with the SEC
<p align="left">REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on F
Mar 30, 2026
earnings
Alvotech Publishes 2025 Annual Report
<p><b>REYKJAVIK, </b><b>ICELAND (March 30, 2026) </b>— Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is
Mar 18, 2026
earnings
Alvotech Q4 2025 and Full Year 2025 Financial Results
<p><b>A</b> <b>supplemental long</b><b>‑</b><b>form earnings release providing additional operational details and business update for Q4 2025 and the
Mar 18, 2026
earnings
Alvotech Q4 2025 and Full Year 2025 Financial Results
<p>REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- </p> <p><strong>Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)</strong><br
Mar 18, 2026
earnings_calendar
ALVO Q4 2025 Earnings After Market Close — 2026-03-18